GLP-1 & Metabolic
Tirzepatide vs Semaglutide: What a 2026 Comparison Found
A 2026 indirect comparison associated tirzepatide with greater weight reduction than semaglutide, while highlighting the limits of cross-trial evidence.
GLP-1 RAs in Lumbar Fusion: 7 Cohorts Reviewed
GLP-1 receptor agonist exposure before lumbar fusion showed no statistically significant increase in the reviewed postoperative outcomes.
Semaglutide in HIV: 108 Participants, 32 Weeks
Semaglutide did not change the trial's measured vascular markers over 32 weeks, while ASCVD risk score and hsCRP differed from placebo.
Retatrutide in PWS: One 18-Month Case
Retatrutide began a sequential incretin case report in Prader-Willi syndrome, but the 18-month result cannot isolate one compound's contribution.
Semaglutide: SELECT Results by Frailty Status
Semaglutide showed no detectable difference in SELECT cardiovascular results across baseline frailty categories in a new post-hoc analysis.
Tirzepatide in HS: Signals From a TriNetX Cohort
Tirzepatide or GLP-1RA exposure was associated with different two-year outcomes in a matched hidradenitis suppurativa cohort.
Retatrutide + Cagrilintide: Rat Study Beats Singles
Retatrutide plus cagrilintide outperformed matched monotherapies for weight and metabolic measures in obese male rats.
GLP-1 Receptor Agonists: One Circuit, Two Effects
GLP-1 receptor agonists engaged one brainstem circuit for both reduced feeding and aversion in a new preclinical study.
Tirzepatide: 22,104 Matched Bariatric-Surgery Patients
Tirzepatide or GLP-1RA use before bariatric surgery was associated with fewer 90-day cardiorenal events in 22,104 matched patients.
Tirzepatide: 415 Matched Knee-Arthroplasty Pairs
Tirzepatide and semaglutide showed similar 90- and 180-day postoperative outcomes in 415 matched pairs undergoing knee arthroplasty.